Navigation Links
CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc.
Date:9/16/2009

The goal of Cellecta's second project with RPCI is to develop, optimize, and perform high-throughput insertional mutagenesis screens to identify potential cancer drug targets.

Mountain View, CA (PRWEB) September 16, 2009 -- Cellecta, Inc., a biotech contract research company which performs high-throughput (HT) RNAi and peptide genetic screens for novel therapeutic target and drug discovery, announced today that it has been awarded a subcontract to assist the scientists at Roswell Park Cancer Institute and Health Research, Inc. in developing a new technology for the discovery of cancer-related genes using HT insertional mutagenesis.

The Principal Investigator of this NIH-funded study, Dr. Eugene Kandel, states "There are many people who can appreciate new ideas about sophisticated molecular technologies when these are described on paper. There are some people who can implement such ideas in practice. And there are very few who can do it in a way that is robust, reproducible and easy for others to follow. That is why I am very happy to have the scientists of Cellecta helping me in the development of the new gene discovery method. These people were behind some of the most innovative techniques that had been popularized by renowned biotech companies, and now I am hoping for the same success for our method as well."

The Founder, CEO, and Scientific Director of Cellecta, Dr. Alex Chenchik, says that "Roswell Park Cancer Institute and Health Research, Inc. have both demonstrated a high level of confidence in Cellecta with this contract award, and we look forward to combining our efforts to develop a sophisticated and robust technology to accelerate the discovery of cancer-related genes."

About Cellecta, Inc.

Cellecta was founded in April of 2006 with a mission to develop the most advanced high-throughput (HT) RNAi and peptide screen technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs. The privately owned contract research service company is headed by an experienced management and product development team with a good product development track record, a network of outside scientific collaborators, and prior experience in start-up company operations. The team's six years of experience performing HT RNAi screens with pooled lentiviral shRNA libraries designed for HT sequencing, HT screening for bioactive peptides, HT functional validation of shRNA, stable cell line development, and HT insertional mutagenesis has resulted in some of the most advanced technologies available, developed in collaboration with opinion leaders and with funding from nine NIH SBIR grants. For more information, visit the Cellecta website, call 1-877-938-3910, or email us at info(at)cellecta(dot)com.

About Roswell Park Cancer Institute

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation's leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit the Roswell Park Cancer Institute website, call 1-877-ASK-RPCI (1-877-275-7724,) or email askrpci(at)roswellpark(dot)org.

About Health Research, Inc.

Health Research, Incorporated (HRI) is a not-for-profit corporation affiliated with the New York State Department of Health (DOH) and the Roswell Park Cancer Institute (RPCI), a leading cancer research center located in Buffalo, NY. HRI's mission is to assist DOH and RPCI to effectively evaluate, solicit, and administer external financial support for DOH and RPCI projects and to disseminate the benefits of DOH expertise through programs such as technology transfer.

# # #

Read the full story at http://www.prweb.com/releases/cellecta-rpci-hri/insertional-mutagenesis/prweb2584394.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
5. Global Experts Explore Entire Spectrum of Aids Vaccine Development
6. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
7. Vical Names Andrew de Guttadauro Vice President, Corporate Development
8. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
9. SemBioSys updates Apo AI development program
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc.
(Date:2/9/2016)... , ... February 08, 2016 , ... ... testing services, announced today the launch of its revamped and improved website. In ... language service solutions, the redesigned website will better communicate how the company designs ...
(Date:2/9/2016)... ... ... The American Academy of Thermology (AAT) has announced that for the ... Qualification Course for Technicians via a two part webinar on July 30 and August ... of hardware, software, and camera setup/operations, aligns with the in-person member qualification course that ...
(Date:2/9/2016)... , Feb. 9, 2016  DNAtrix, a ... for cancer, announced that its lead product, ... Commission as an orphan medicinal product for ... form of glioma, strikes approximately 25,000 people ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> ...
(Date:2/9/2016)... 9, 2016 Three-Year Initiative Supports Next ... Take Part in Life-Changing Camp Experiences ... to positively affect the lives of children born with rare diseases, ... SHPG ) is announcing a new initiative designed to positively ... as the future of rare disease care. --> To ...
Breaking Biology Technology:
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
Breaking Biology News(10 mins):